Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | GALR2 | O43603 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31613168 | 0.89 | KDM4E (0.46) | KDM4ELMNAMAPTHTTNPSR1 | |
| SCHEMBL30896394 | 0.89 | LMNA (0.46) | KDM4ELMNAMAPTHTTNPSR1 | |
| SCHEMBL11561933 | 0.82 | CYP1A2 (0.43) | KDM4ELMNAMAPTHTTNPSR1 | |
| SCHEMBL30896312 | 0.77 | KDM4E (0.40) | KDM4ELMNAMAPTHTTNPSR1 | |
| SCHEMBL30896380 | 0.77 | ALDH1A1 (0.40) | KDM4ELMNAMAPTHTTALDH1A1 | |
| SCHEMBL588563 | 0.77 | RAB9A (0.62) | KDM4ELMNAMAPTHTTNPSR1 | |
| SCHEMBL2481608 | 0.77 | RAB9A (0.52) | KDM4ELMNAMAPTHTTALDH1A1 | |
| SCHEMBL13916682 | 0.77 | KDM4E (0.69) | KDM4ELMNAMAPTHTTALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL20358007 | 0.76 | RAB9A (0.60) | KDM4ELMNAMAPTHTTNPSR1 | |
| Ammonia Solution, Strong SCHEMBL29063683 | 0.76 | RAB9A (0.51) | KDM4ELMNAMAPTHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1228072-B1 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | YISSUM RES DEV CO (IL) | 2005-09-28 | — | — | EP | disclosed |
| US-20040157852-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-20040132725-A1 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same | LEVITZKI ALEXANDER (IL) | 2004-07-08 | — | — | US | disclosed |
| US-6673798-B2 | PLATELET DERIVED GROWTH FACTORS (PDGF); 1,2-DIMETHYL-6-(2-THIOPHENE)IMIDAZOLO(5,4-G)QUINOXALINE PREPARATIONS FOR EXAMPLE; USE TREATING PROLIFERATIVE MALIGNANT AND NON-MALIGNANT DISEASES; STENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-01-06 | — | — | US | disclosed |
| US-6656940-B2 | Treatment of cancer. | SUGEN, INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1228072-A4 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | YISSUM RES DEV CO (IL) | 2003-05-07 | — | — | EP | disclosed |
| EP-1228072-A1 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | Yissum Research Development Company of the Hebrew University of Jerusalem (IL) | 2002-08-07 | — | — | EP | disclosed |
| US-20020055511-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | SUGEN, INC. | 2002-05-09 | — | — | US | disclosed |
| US-6358954-B1 | IMIDAZO(4,5-G)QUINOXALINE DERIVATIVES; ANTITUMOR, ANTICARCINOGENIC AND ANTIPROLIFERATIVE AGENTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-03-19 | — | — | US | disclosed |
| US-20020028817-A1 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2002-03-07 | — | — | US | disclosed |
| US-6329375-B1 | ENZYME INHIBITORS AND ANTIINFLAMMATORY AGENTS | SUGEN, INC. | 2001-12-11 | — | — | US | disclosed |
| WO-2001034607-A1 | PDGF RECEPTOR KINASE INHIBITORY COMPOUNDS, THEIR PREPARATION, PURIFICATION AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-05-17 | — | — | WO | disclosed |
| WO-1999007701-A1 | TRICYCLIC QUINOXALINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS | SUGEN, INC. (US) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055511-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | PDXK, TK1, ABL1 | KDM4E 1597/4885LMNA 3816/4885MAPT 3699/4885 |
| US-20020028817-A1 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same | PDGFRB, PDGFRA, PDGFA | KDM4E 2256/4885LMNA 3811/4885MAPT 3006/4885 |
| US-20040157852-A1 | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors | PDXK, TK1, ABL1 | KDM4E 1597/4885LMNA 3816/4885MAPT 3699/4885 |
| US-20040132725-A1 | PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same | PDGFRB, PDGFRA, PDGFA | KDM4E 2256/4885LMNA 3811/4885MAPT 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.